OmVenture

24.4K posts

OmVenture banner
OmVenture

OmVenture

@OmVenture

Peptides, proteomics, genomics, biotech, pharma for drugs, medical, prevention, diagnostics, healthcare & longevity using super intelligence automation ventures

San Francisco, USA Katılım Eylül 2009
2.7K Takip Edilen10.4K Takipçiler
Sabitlenmiş Tweet
OmVenture
OmVenture@OmVenture·
@davidasinclair Be a living legend! Longevity isn’t about increasing older population It’s about getting an extended life with rich experiences & newfound opportunities Achieve abundant physical, mental & social benefits Reward yourself with an entirely new happier life Stay youth forever!
OmVenture@OmVenture

@LivingForever8 Live Forever! Ultimate goal is to put our destiny in our hands, not in metaphorical hands of fate, to live as long as we wish Singularity is possible when merge with AI Compelling reasons, rationally explained Roadmap for researchers Foster partnerships for pooling resources

English
16
0
22
9.9K
OmVenture retweetledi
Prachee Avasthi
Prachee Avasthi@PracheeAC·
I used GPT 5.6 to use what it knows about me to make a short list of things I shouldn’t do anymore and it was painfully accurate. - researching reversible decisions as though they are permanent and consequential - refining language after it is already precise and the underlying idea is accurate, clear, and unlikely to be misunderstood - revisiting decisions because I want the rationale to be completely airtight - giving intellectually interesting ideas the same attention before they have earned priority Touché, GPT
GREG ISENBERG@gregisenberg

i keep a running doc called “things i’m not doing anymore” and look at it monthly really simple way to live a happier & more productive life

English
3
1
13
3.1K
OmVenture retweetledi
Avi Roy
Avi Roy@agingroy·
Up to a third of the weight you lose on Ozempic isn't fat. It's muscle. That's a problem, so drug companies raced to fix it, and they're winning. Add a muscle-saving drug to a shot like Ozempic and the weight you lose flips to about 92% fat, with less than half the muscle loss. @EliLillyandCo's bimagrumab already does this, and @ScholarRock and @Regeneron are close behind. Wall Street analysts at TD Cowen think that market alone hits $30 billion by 2035. And that's only the start. Fat loss was the first frontier, and it's basically won, with even stronger drugs coming. Muscle is the second. The third is sleep. New drugs can flip the brain's wake switch, turning alertness up in the morning or sleep on at night, close to on demand. Lilly just paid $6.3 billion for @centessa to lead it. Fat, muscle, sleep. @EliLillyandCo is worth a trillion dollars, the most valuable drug company alive, and it's betting on all three. We spent a decade learning to shed fat. Next, we learn to keep our muscles and switch sleep on and off.
Ashwin Sharma@Ashwinreads

exactly how big is the muscle preserving market going to be?

English
4
7
21
11.2K
OmVenture retweetledi
Vega Shah
Vega Shah@dr_alphalyrae·
Got a peptide treatment today to treat a cavity, and the mechanism is one of those things that feels almost too elegant to be real. An amelogenin-derived peptide penetrates the cavity, forming a matrix that rebuilds hydroxyapatite crystals. It does so by attracting calcium and phosphate from your own saliva to naturally remineralize and cover up the cavity. But sadly insurance doesn’t cover this non invasive, preventative and relatively affordable treatment. Kinda sucks that we are so behind in letting everyone have access to this type of treatment easily.
English
34
73
1.2K
69.5K
OmVenture retweetledi
Riya Bisht
Riya Bisht@b1shtream·
If we really want to speed up the scientific progress then we need to rethink the way we do science in our labs. We are building Bangalore's Lab Automators community(inspired by Bay Area Lab Automators). Open for everyone who's exploring and building in wetlab automation/ biotech/Physical AI x Bio x Robotics. Comment here or DM. I'll send you an invite. Now it's time to have one chapter here in India 🧪+🦾
English
25
8
115
4.4K
OmVenture retweetledi
Elliot Roth || SF
Elliot Roth || SF@ThatMrE·
Great overview of the flood of philanthropic capital about to hit the streets
Alex S. Araki@alexsaraki

New blog post: The Race to Allocate One Trillion Dollars in Philanthropic Capital Within the next year, thousands of young millionaires (25-40y.o.) will be minted in essentially one zip code, collectively holding over $1T in new assets. Between SpaceX, OpenAI, and Anthropic, I estimate that we'll see ~3,000 new decamillionaires, ~500 centimillionaires, and ~40 billionaires minted across the three IPOs. But philanthropy as it exists today is built for a donor profile that doesn't match these people. Most orgs outside SF are defaulting to strategies that are both presumptuous and unscalable. In my new piece, I describe where the money will likely go by default (DAFs and EA allocators), why that's insufficient, and strategies to create a "Silicon Valley for Public Goods". In the end, talent will be the moat. Today, there are maybe a ~dozen visible people who can effectively match ambitious philanthropic founders to funders. We'll need dozens to hundreds within the next one to two years. But the window is closing. (full link to article in comments)

English
2
2
12
2.1K
OmVenture retweetledi
Barsha
Barsha@BarshaPanda·
The problem with our times is that there's a lot more talk of ambition than there is real ambition. And there’s even less resolve to see it through. Talk of big goals and grand obsessions dies easy the moment you have to dig in and deliver. Because delivering is a long, frustrating sequence of tiny steps and constant setbacks. With zero assurance that you'll make it through. Real ambition needs resolve to see it through. And resolve is developed, not switched on. It doesn't fire up on command. It's built on mental and physical capacity, and a hard-earned ability to bounce back.  That takes a lot more than talking about shiny goals. But resolve is also your only friend in the trenches. Go after resolve first.  Understand it. Practise it. Then pick the goal. Your odds of success will shoot up. And the journey won't break you. Ambition is loud.  Resolve is quiet.  But resolve is what wins.
English
9
6
26
681
OmVenture retweetledi
James Dyett
James Dyett@dyett·
In the last few months, Eli Lilly, Pfizer, and Novartis have all chosen to partner with @chaidiscovery. Great momentum!
Chai Discovery@chaidiscovery

We’re delighted to announce our collaboration with @Novartis. Building on a year-long technical engagement, we’re expanding our collaboration with Novartis to support broader deployment of our technology across multiple therapeutic programs. Novartis will gain access to our latest models for prediction and design, including Chai-3.

English
1
5
91
12.1K
OmVenture retweetledi
Avi Roy
Avi Roy@agingroy·
Everyone wants to sell peptides, but nobody will fund even a basic clinical trial on them. Wonder why?
English
6
6
60
6.4K
OmVenture retweetledi
Avi Roy
Avi Roy@agingroy·
Ozempic and Wegovy are often talked about as vanity drugs. In reality, they represent one of the biggest shifts modern medicine has made in a generation, and almost nobody describes them that way. For decades, every blockbuster appetite drug was eventually pulled for harming people. Fen-phen damaged heart valves and was banned in 1997. Sibutramine increased heart attacks and strokes and was gone by 2010. Lorcaserin was pulled in 2020 after a cancer signal. The pattern seemed fixed: if a drug was strong enough to switch off hunger, it was strong enough to hurt you. Then semaglutide, the molecule in Wegovy, did the opposite. In a trial of 17,604 people who were overweight or obese and had heart disease but not diabetes, it cut heart attacks, strokes, and cardiac deaths by 20%. A sister trial slowed kidney disease by 24%. For the first time, a weight-loss drug protects organs instead of damaging them. That's why the knock-on effects are showing up everywhere, from women's employment to a £780m drop in UK supermarket spending, which this @FT Economics Show episode explores. Obesity is no longer a willpower story. It's a treatable disease.
Soumaya Keynes@SoumayaKeynes

The economics of weight loss, with Rebecca Diamond and Claer Barrett ift.tt/ouTjDil

English
7
12
79
7K
OmVenture retweetledi
Mgoes (bio/acc 🤖💉)
Mgoes (bio/acc 🤖💉)@m_goes_distance·
biotech is ripping in 2026 just look at what just dropped this week: - a naturally occurring bacterium from amphibian intestines completely eliminated colorectal tumors in mice with a single treatment, attacking cancer cells and activating the immune system at the same time - scientists cracked how bacteria naturally manufacture multiple versions of powerful anti-cancer drugs, opening the door to engineering entirely new cancer treatments inspired by nature - an experimental drug called DT-109 reversed severe fatty liver disease in animal studies by repairing the gut, a potential new class of treatment for MASH - a silicon chip that writes dozens of DNA sequences simultaneously using electricity and water-based enzymes just replaced conventional DNA manufacturing with something dramatically cleaner and faster - researchers discovered mRNA cancer vaccines recruit an immune cell nobody knew was involved, overturning a long-held assumption about how the vaccines actually work - two separate biotech companies, Paterna and Conception, are now growing human sperm and immature eggs in a lab from patient cells the timeline is bio/acc
English
12
29
208
9.8K
OmVenture retweetledi
Avi Roy
Avi Roy@agingroy·
American obesity climbed for sixty years: 13% of adults in 1960, 40% by 2023. It rose through every food pyramid, sugar tax, gym campaign, and diet book. Nothing slowed it. Gallup now puts it at 36.4%, down from a peak of 39.9%, the first sustained decline in the twenty years it has tracked the rate, just as GLP-1 use rose from 3% to 11% of American adults. Obesity kills about half a million Americans a year, or 1,300 a day, through the heart disease, cancers, and diabetes it causes. On 1 July, Medicare started paying $50 a month for these drugs: the Wegovy and Zepbound shots, plus Foundayo, the new daily pill. BMI 35 qualifies on its own. BMI 30 with high blood pressure, heart failure, or kidney disease. BMI 27 with prediabetes, or a prior heart attack or stroke. Most people miss that last tier.
Jen Can NuSH@JCanNuSH

Earlier this week, Gallup said that 11% of US adults polled were using GLP-1s. There are around 267 million adults in the US. If that 11% number is “real”, that would be roughly 30 million US patients. The problem: in their last quarterly report (Q1 2026), $LLY said the US incretin market was around 2.4 million a week - or roughly 10 million a month - and that includes T2D and pediatric scripts. So is this just a giant sampling issue, or are 20 million patients on compound or RUO? It’s probably a mix of both, but this potentially points to a big issue for pharma. I will note that the same poll indicated that 68% said they were on branded, but it’s possible patients may be shy or not even know the difference. (I’m sure Lilly and Novo are hoping those responses are honest.) That might indicate the real total number of patients on GLP-1s is closer to around 15 million, with just 5 million on compound. 🤷‍♀️

English
0
7
23
3.3K
OmVenture
OmVenture@OmVenture·
@ramblingsloa Also, enough food, sleep, physical comforts and spiritual advances
English
0
0
4
49
Ramblings
Ramblings@ramblingsloa·
The seven wonders of the world: To see, to hear, to touch, to taste, to feel, to laugh, to love ❤️
Ramblings tweet media
English
35
613
1.7K
19.9K
OmVenture retweetledi
Vaibhav Sisinty
Vaibhav Sisinty@VaibhavSisinty·
Satya Nadella just warned every company using AI: you are paying twice. Once with money. Again with something far more valuable. He published an article introducing something called the Reverse Information Paradox. And it changes how you think about every AI tool your company uses. Nobel laureate Kenneth Arrow described the original paradox: a seller risks giving away knowledge just to sell it. Nadella says AI flips this completely. In the AI age, the buyer gives away knowledge just to use what they bought. Every time your team uses Claude or GPT at work, every prompt reveals what you are building. Every correction teaches the model what good looks like inside your company. Every eval shows what you value. Every trace exposes your workflow. The model provider learns more about you with every interaction. You learn almost nothing about what they are learning in return. Your corrections are distilled institutional know-how. The kind a competitor could never buy. And it leaks trace by trace, correction by correction, without you noticing. His line: "You can offload a task. You can offload a job. But you can never offload your learning." If the model provider disappears tomorrow, do you still own the intelligence your team built on top of it? Your evals. Your memory. Your traces. Your workflows. Or did all of that compound inside someone else's infrastructure? In the cloud era, companies accumulated data. In the AI era, they accumulate learning. Right now, most of that learning is compounding inside the model provider. Not inside the company paying for it. The CEO pushing AI harder than anyone just told you to protect your knowledge from the very tools he is selling you. That should tell you everything.
Satya Nadella@satyanadella

x.com/i/article/2076…

English
84
412
2.7K
1.3M
OmVenture retweetledi
Mgoes (bio/acc 🤖💉)
Mgoes (bio/acc 🤖💉)@m_goes_distance·
If you're building/investing in biotech, bookmark this three patterns you can't sleep on: 1. regulators are legitimizing entirely new categories of medicine Life Biosciences dosed the first patient in a cellular reprogramming trial the trial matters. the regulatory precedent might matter even more once regulators start creating pathways for therapies targeting aging biology, the conversation changes. 2. capital has moved years ahead of clinical proof. NewLimit is worth billions before entering the clinic. Retro is already dosing humans. Isomorphic Labs, Chai Discovery, and others are attracting frontier-scale capital around AI-native biology. the question quietly shifted from "Will this work?" to "Who builds it first?" 3. the "one drug for everyone" model is dying used to be cancer, now it's aging too. sequencing costs dropped a millionfold. precision medicine is eating blunt-force treatment across the board. the thing to actually watch: Life Biosciences results drop later this year that's the moment this either gets validated or the whole thesis resets if you're investing around this thesis, DM me bio/acc.
English
4
14
56
5.1K
OmVenture retweetledi
clare ❤️‍🔥
clare ❤️‍🔥@clarejtbirch·
love this. im funding: - Scale for mouse models - Palantir for long-term biobanks - Vercel for cell-free expression - Figma for synthetic promoters - Cursor for peptide design
Mgoes (bio/acc 🤖💉)@m_goes_distance

biotech ideas we're funding rn: - Stripe for gene therapies. - GitHub for wet labs. - Cloudflare for clinical trials. - Plaid for biomarkers. - Bloomberg for biological age. - Costco for GMP manufacturing. - Anduril for biosecurity. - NVIDIA for programmable biology. - Cursor for molecular biology. - A "WHOOP for cells," not steps. If infrastructure precedes the science, biotech accelerates 10x faster if youre backing this wave, i'd love to chat.

English
12
5
179
31.6K
OmVenture
OmVenture@OmVenture·
Endless Divinity
OmVenture tweet mediaOmVenture tweet mediaOmVenture tweet mediaOmVenture tweet media
English
0
0
3
121
OmVenture
OmVenture@OmVenture·
Add your favorite picture here
OmVenture tweet media
English
11
15
30
0
OmVenture
OmVenture@OmVenture·
Climax/Ultimate Love Unconditional Trust and Faith Nectar from Gopis Raas Leela Divinity from Radha Krishna Krishna is the ideal unconditional true lover, revealing all aspects of love. It’s difficult to understand a love so pure that it wants nothing, expects nothing. Thread..
English
34
111
159
0

Keşfet

@EliLillyandCo @ScholarRock @Regeneron @centessa @chaidiscovery @FT @ramblingsloa @elonmusk